IP Group, CIC and Johnson & Johnson have returned for a $52.2m series B round in Inivata, a spinout of Cancer Research UK and University of Cambridge.

Inivata, a UK-based oncology genomics technology spinout, closed a £39.8m ($52.2m) series B round today backed by Cambridge Innovation Capital (CIC), the patient capital affiliate of University of Cambridge.
Commercialisation firm IP Group also took part, as did Johnson & Johnson Innovation – JJDC, the healthcare group’s corporate venturing subsidiary, and Woodford Patient Capital Trust, operated by fund manager Woodford Investment Management.
RT Ventures also contributed to the round, which was oversubscribed and raised over two tranches. The…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in